Please provide your email address to receive an email when new articles are posted on . Infliximab induction and maintenance were associated with “potentially improved efficacy outcomes” vs.

ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

CHICAGO — Infliximab (multiple brands) was associated with fewer discontinuations for lack of efficacy than vedolizumab (Entyvio) during the maintenance phase of ulcerative colitis treatment, an ...

Please provide your email address to receive an email when new articles are posted on . Incidences of hospitalizations and surgeries were lowest with the vedolizumab-adalimumab sequence in UC and CD.

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

An infliximab biosimilar (infliximab-axxq) delivered via subcutaneous injection was superior to intravenous vedolizumab (Entyvio) for induction and maintenance therapy of Crohn's disease (CD), ...

Moderate to severe disease causes substantial morbidity in inflammatory bowel disease (IBD). The approach to pharmacotherapy for patients with moderate to severe ulcerative colitis and Crohn’s disease ...

The San Diego-based pharmaceutical company Prometheus Laboratories has launched PROMETHEUS Anser VDZ, a monitoring test for inflammatory bowel disease patients using vedolizumab. 1. The PROMETHEUS ...